NEKTAR THERAPEUTICSNN

NEKTAR THERAPEUTICS

0.7590EURD
−0.0570−6.99%
As of today at 07:01 GMT
EUR
No trades
See on Supercharts
Next report date
Today
Report period
Q4 2024
EPS estimate
−0.13 EUR
Revenue estimate
‪35.42 M‬ EUR
Market capitalization
‪137.25 M‬EUR
−0.7520EUR
‪−250.11 M‬EUR
‪81.65 M‬EUR
‪177.79 M‬
Beta (1Y)
2.92
Employees (FY)
137
Change (1Y)
−79 −36.57%
Revenue / Employee (1Y)
Net income / Employee (1Y)

About Nektar Therapeutics


CEO
Howard W. Robin
Headquarters
San Francisco
Website
Founded
1990
FIGI
BBG000BNHFR5
Nektar Therapeutics is a biotechnology company, which engages in the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. It also focuses on immunology and unparalleled expertise in polymer chemistry to create one-of-a-kind, highly-selective medicines with optimal therapeutic benefit. The company was founded in 1990 and is headquartered in San Francisco, CA.
Performance
‪−230%‬
‪−210%‬
‪−190%‬
‪−170%‬
‪−150%‬
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
‪‪−75.00 M‬‬
‪‪−50.00 M‬‬
‪‪−25.00 M‬‬
‪0.00‬
‪‪25.00 M‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪‪−34.00 M‬‬
‪‪−17.00 M‬‬
‪0.00‬
‪‪17.00 M‬‬
‪‪34.00 M‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪‪−34.00 M‬‬
‪‪−17.00 M‬‬
‪0.00‬
‪‪17.00 M‬‬
‪‪34.00 M‬‬
Debt level and coverage
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
‪‪−80.00 M‬‬
‪0.00‬
‪‪80.00 M‬‬
‪‪160.00 M‬‬
‪‪240.00 M‬‬
Debt
Free cash flow
Cash & equivalents
Earnings
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪−0.24‬
‪−0.18‬
‪−0.12‬
‪−0.06‬
‪0.00‬
Actual
Estimate

No news here

Looks like there's nothing to report right now

See all ideas 

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange NEKTAR THERAPEUTICS stocks are traded under the ticker ITH.
We've gathered analysts' opinions on NEKTAR THERAPEUTICS future price: according to them, ITH price has a max estimate of 6.74 EUR and a min estimate of 1.25 EUR. Watch ITH chart and read a more detailed NEKTAR THERAPEUTICS stock forecast: see what analysts think of NEKTAR THERAPEUTICS and suggest that you do with its stocks.
ITH reached its all-time high on Mar 9, 2018 with the price of 89.7500 EUR, and its all-time low was 0.3900 EUR and was reached on Nov 29, 2023. View more price dynamics on ITH chart.
See other stocks reaching their highest and lowest prices.
Yes, you can track NEKTAR THERAPEUTICS financials in yearly and quarterly reports right on TradingView.
NEKTAR THERAPEUTICS is going to release the next earnings report on Feb 27, 2025. Keep track of upcoming events with our Earnings Calendar.
ITH earnings for the last quarter are −0.16 EUR per share, whereas the estimation was −0.18 EUR resulting in a 9.55% surprise. The estimated earnings for the next quarter are −0.13 EUR per share. See more details about NEKTAR THERAPEUTICS earnings.
NEKTAR THERAPEUTICS revenue for the last quarter amounts to ‪21.67 M‬ EUR, despite the estimated figure of ‪17.22 M‬ EUR. In the next quarter, revenue is expected to reach ‪35.42 M‬ EUR.
ITH net income for the last quarter is ‪−33.28 M‬ EUR, while the quarter before that showed ‪−48.89 M‬ EUR of net income which accounts for 31.92% change. Track more NEKTAR THERAPEUTICS financial stats to get the full picture.
No, ITH doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Feb 27, 2025, the company has 137.00 employees. See our rating of the largest employees — is NEKTAR THERAPEUTICS on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. NEKTAR THERAPEUTICS EBITDA is ‪−116.92 M‬ EUR, and current EBITDA margin is −143.82%. See more stats in NEKTAR THERAPEUTICS financial statements.
Like other stocks, ITH shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade NEKTAR THERAPEUTICS stock right from TradingView charts — choose your broker and connect to your account.